Dr. Lal Path Labs Ltd. (LALPATHLAB) - Total Assets

Latest as of March 2026: Rs31.46 Billion INR ≈ $340.23 Million USD

Based on the latest financial reports, Dr. Lal Path Labs Ltd. (LALPATHLAB) holds total assets worth Rs31.46 Billion INR (≈ $340.23 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check cash flow reinvestment rate of Dr. Lal Path Labs Ltd. to assess the company's total reinvestment commitment from operating cash flow.

Dr. Lal Path Labs Ltd. - Total Assets Trend (2011–2026)

This chart illustrates how Dr. Lal Path Labs Ltd.'s total assets have evolved over time, based on quarterly financial data. Explore Dr. Lal Path Labs Ltd. (LALPATHLAB) long-term investment share to see how much of total assets are deployed in long-term investments.

Dr. Lal Path Labs Ltd. - Asset Composition Analysis

Current Asset Composition (March 2026)

Dr. Lal Path Labs Ltd.'s total assets of Rs31.46 Billion consist of 49.8% current assets and 50.2% non-current assets.

Asset Category Amount (INR) % of Total Assets
Cash & Equivalents Rs0.00 28.9%
Accounts Receivable Rs1.12 Billion 3.6%
Inventory Rs439.00 Million 1.4%
Property, Plant & Equipment Rs0.00 0.0%
Intangible Assets Rs1.93 Billion 6.1%
Goodwill Rs5.48 Billion 17.4%

Asset Composition Trend (2011–2026)

This chart illustrates how Dr. Lal Path Labs Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Dr. Lal Path Labs Ltd. stock valuation.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Dr. Lal Path Labs Ltd.'s current assets represent 49.8% of total assets in 2026, an increase from 25.9% in 2011.
  • Cash Position: Cash and equivalents constituted 28.9% of total assets in 2026, up from 2.6% in 2011.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 23.0% of total assets, a decrease from 24.0% in 2011.
  • Asset Diversification: The largest asset category is goodwill at 17.4% of total assets.

Dr. Lal Path Labs Ltd. Competitors by Total Assets

Key competitors of Dr. Lal Path Labs Ltd. based on total assets are shown below.

Company Country Total Assets
Fleury S.A.
SA:FLRY3
Brazil R$13.33 Billion
Wuhan Thalys Med Tech Co Ltd
SHG:603716
China CN¥1.74 Billion
Spectral Med Inc
TO:EDT
Canada CA$8.12 Million
Bcal Diagnostics Ltd
AU:BDX
Australia AU$7.17 Million
Genetic Signatures Ltd
AU:GSS
Australia AU$49.04 Million
ALPHAHELIX MOL.DIAGN. SK1
F:4MB
Germany €13.12 Million
Sonic Healthcare Ltd
AU:SHL
Australia AU$17.03 Billion
Australian Clinical Labs Ltd
AU:ACL
Australia AU$562.50 Million

Dr. Lal Path Labs Ltd. - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 3.48 3.39 4.18
Quick Ratio 3.38 3.30 4.02
Cash Ratio 0.00 2.08 0.00
Working Capital Rs11.16 Billion Rs9.61 Billion Rs8.71 Billion

Dr. Lal Path Labs Ltd. - Advanced Valuation Insights

This section examines the relationship between Dr. Lal Path Labs Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 11.54
Latest Market Cap to Assets Ratio 0.10
Asset Growth Rate (YoY) 15.8%
Total Assets Rs31.46 Billion
Market Capitalization $3.00 Billion USD

Valuation Analysis

Below Book Valuation: The market values Dr. Lal Path Labs Ltd.'s assets below their book value (0.10x), which may indicate investor concerns about asset quality or future growth.

Rapid Asset Growth: Dr. Lal Path Labs Ltd.'s assets grew by 15.8% over the past year, indicating significant expansion of the company's resource base.

Annual Total Assets for Dr. Lal Path Labs Ltd. (2011–2026)

The table below shows the annual total assets of Dr. Lal Path Labs Ltd. from 2011 to 2026.

Year Total Assets Change
2026-03-31 Rs31.46 Billion
≈ $340.23 Million
+15.80%
2025-03-31 Rs27.17 Billion
≈ $293.81 Million
+10.62%
2024-03-31 Rs24.56 Billion
≈ $265.60 Million
+2.95%
2023-03-31 Rs23.86 Billion
≈ $257.98 Million
+1.37%
2022-03-31 Rs23.53 Billion
≈ $254.49 Million
+41.65%
2021-03-31 Rs16.61 Billion
≈ $179.67 Million
+20.89%
2020-03-31 Rs13.74 Billion
≈ $148.63 Million
+26.03%
2019-03-31 Rs10.90 Billion
≈ $117.93 Million
+18.68%
2018-03-31 Rs9.19 Billion
≈ $99.37 Million
+20.25%
2017-03-31 Rs7.64 Billion
≈ $82.64 Million
+22.22%
2016-03-31 Rs6.25 Billion
≈ $67.62 Million
+31.54%
2015-03-31 Rs4.75 Billion
≈ $51.40 Million
+35.22%
2014-03-31 Rs3.52 Billion
≈ $38.02 Million
+30.67%
2013-03-31 Rs2.69 Billion
≈ $29.09 Million
+51.95%
2012-03-31 Rs1.77 Billion
≈ $19.15 Million
+4.36%
2011-03-31 Rs1.70 Billion
≈ $18.35 Million
--

About Dr. Lal Path Labs Ltd.

NSE:LALPATHLAB India Diagnostics & Research
Market Cap
$3.00 Billion
Rs277.67 Billion INR
Market Cap Rank
#5010 Global
#223 in India
Share Price
Rs1662.90
Change (1 day)
+0.67%
52-Week Range
Rs1307.60 - Rs3473.50
All Time High
Rs4119.53
About

Dr. Lal PathLabs Limited operates laboratories for carrying out pathological investigations in India and internationally. The company provides pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It also offers phlebotomi… Read more